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FIBRILLATION IN THE NETHERLANDS: 
A MODELING APPROACH
Bhattacharyya SK1, Delea TE2, Vera M2, Oster G2, Kuy AVD3
1Procter & Gamble Pharmaceuticals, Cincinnati, OH, USA; 
2Policy Analysis Inc., Boston, MA, USA; 3Loon op Zand, The 
Netherlands
OBJECTIVES: To estimate the direct costs of maintaining
normal sinus rhythm (NSR) in patients with atrial fibrilla-
tion (AF) with four antiarrhythmic (AA) drugs (sotalol,
amiodarone, flecainide, and propafenone) in the Nether-
lands (NL).
METHODS: A Markov model, with a one month cycle
length and a one year treatment duration, was used to esti-
mate expected costs of maintaining NSR. An expert panel
of cardiologists was interviewed to collect data on the per-
ceived safety and efficacy of the drugs, resource use (inpa-
tient and outpatient visits, tests and procedures) for recur-
rence of AF, treatment initiation, monitoring, and side
effects. Cost data were obtained principally from the Cen-
tral Organization for Tariffs in Health Care and the Na-
tional Association of Pharmacists. Costs were estimated
separately by drugs and for patients with and without con-
comitant structural heart disease (SHD), then weighted by
the joint distribution of presence or absence of SHD, spe-
cific use of a drug in these two populations, and/or market
share of AA drugs.
RESULTS: The weighted average annual cost of maintain-
ing NSR in an AF patient was US$2,181.31. Inpatient
treatment costs, dominated mainly by costs of symptom
recurrence and therapy initiation, ranged from 78%
(flecainide) to 92% (sotalol) of total costs. Costs of moni-
toring and side effects were the highest for amiodarone
and sotalol, respectively. Drug costs, ranging from $60 for
sotalol to $252 for flecainide, were the minor contributors
to the total costs. In patients with SHD, annual costs of
maintaining NSR were $2,685 and $2,505 for sotalol and
amiodarone, the two most common drugs in the NL, re-
spectively.
CONCLUSIONS: The estimated annual cost of maintain-
ing NSR in patients with AF in the NL is as high as
US$2,685 per patient. Relatively lower AA drug costs are
offset by significant medical treatment costs, particularly
for inpatient therapy initiation and recurrence of disease
symptoms.
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THE COST-EFFECTIVENESS OF CHOLESTEROL-
LOWERING TREATMENT IN THE PRIMARY 
PREVENTION OF CORONARY HEART DISEASE: 
THE CASE OF A COMPREHENSIVE DIETARY 
INTERVENTION PROGRAM
Long K
Section of Health Services Evaluation, Mayo Clinic, Rochester, 
MN, USA
OBJECTIVES: No studies to date have addressed the cost-
effectiveness of lifelong dietary treatment when adminis-
tered in “real world” community practice. This study ex-
amines whether a comprehensive intervention program to
detect and treat, through dietary therapy, hypercholester-
olemic patients is a cost-effective approach in the primary
prevention of morbidity and mortality from coronary
heart disease (CHD).
METHODS: I developed a multidimensional model of
CHD incidence using results from the Physician-Assisted
Cholesterol Education Program (PACE), a prospective
randomized trial in rural clinical practice, in combination
with multivariate logistic risk functions from the Framing-
ham Heart Study. The cost and health effects of this di-
etary intervention are projected over a lifetime for patients
with known CHD risk factors. Results were also simulated
for the pharmacologic treatment of lovastatin taken daily
in addition to dietary intervention. Changes in life expect-
ancy, quality-adjusted life expectancy, and incremental
cost-effectiveness ratios ($/QALY), were the primary out-
come measures of interest.
RESULTS: PACE participants, on average, reduced their
total serum cholesterol levels 1.3% (CI 0.43–2.14). Rela-
tive to no treatment, men on dietary treatment gained an
estimated 4 to 26 days of quality-adjusted life expectancy
at an estimated cost-effectiveness of $14,463 to $77,574
($/QALY), depending on the age of treatment initiation.
Women gained an estimated 3 to 19 days with cost-effec-
tiveness ratios from $49,998 to $102,574 ($/QALY). Rel-
ative to dietary treatment alone, the cost-effectiveness of
the combined diet-plus-lovastatin treatment ranged from
$43,620 to $49,776 ($/QALY) in men, and from $52,996
to $74,718 ($/QALY) in women.
CONCLUSIONS: Dietary intervention is a relatively cost-
effective method of CHD prevention and should remain
the preferred treatment option for younger men and
women—especially for those initially at highest risk of
CHD. Combined diet-plus-lovastatin therapy, however, is
the optimal treatment choice for older individuals and for
those who experience a reduced quality of life on stringent
dietary regimes.
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COSTS OF MAINTAINING NORMAL SINUS 
RHYTHM IN PATIENTS WITH ATRIAL 
FIBRILLATION OR FLUTTER IN THE 
UNITED STATES
Bhattacharyya SK1, Delea TE2, Vera M2, Oster G2
1Procter & Gamble Pharmaceuticals, Mason, OH, USA; 2Policy 
Analysis Inc., Brookline, MA, USA
OBJECTIVES: The objective of the study was to estimate
the direct costs of maintaining normal sinus rhythm (NSR)
in patients with atrial fibrillation or flutter (AF/F) with five
antiarrhythmic (AA) agents (amiodarone, flecainide, pro-
pafenone, quinidine, sotalol).
METHODS: A Markov model was used to estimate the
expected costs of maintaining NSR in patients with AF/F
using AA therapies. Estimates of the resource utilization
(inpatient therapy initiation and monitoring, recurrence,
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and side effects), and efficacy and safety of AA agents were
obtained from an expert panel of fifteen cardiologists. Unit
costs were estimated from published studies and Medicare
and state reimbursement rates. Expected costs for each
therapy were estimated for patients with and without struc-
tural heart disease (SHD), then weighted by corresponding
estimates of prescription frequencies to obtain expected
costs for a typical patient.
RESULTS: The annual costs of maintaining NSR in pa-
tients with and without SHD ranged from $3,763 (quini-
dine) to $4,749 (amiodarone) and from $2,912 (quinidine)
to $3,773 (sotalol) per patient, respectively. For a typical
patient, the total annual cost of maintaining NSR was
$3,809. Costs of therapy initiation and side effects were es-
timated to be $1,341 and $1,198, respectively; together,
these constituted 67% of total treatment cost. Costs of in-
patient care represented over 64% of total cost.
CONCLUSIONS: The cost of maintaining NSR with
available AA therapies is $3,809 for a typical AF/F patient.
Costs of inpatient therapy initiation and side effects consti-
tute the majority of the total cost. Total treatment costs are
highest for amiodarone and sotalol in patients with and
without SHD, respectively.
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COST ANALYSIS OF AMLODIPINE VERSUS 
FELODIPINE ER IN THE TREATMENT OF MILD-
TO-MODERATE HYPERTENSION
Berliner E, Radensky P
McDermott, Will & Emery, Miami, FL, USA
OBJECTIVE: To determine drug costs to establish and
maintain treatment for hypertension with amlodipine and
felodipine.
METHODS: Data from published reports of 4 controlled
trials directly comparing amlodipine and felodipine were
analyzed. Three trials were identified from a comprehen-
sive Medline search; one trial was cited as a reference. For
one study, the unpublished study report supplemented in-
formation from the published report. In all 4 trials, sub-
jects with mild-to-moderate hypertension were started on
5 mg of study drug and titrated to higher dosages after 2
to 8 weeks if hypertension was not controlled. Maximum
dosages of amlodipine and felodipine were 10 mg in 3
studies. One study allowed titration to felodipine 20 mg.
In another study, lisinopril was added if hypertension was
not controlled by monotherapy. Data were pooled across
studies to determine the fraction of patients titrated to
greater than 5 mg or dual therapy. For the cost analysis,
average drug costs to establish and maintain treatment
were calculated from dosages during and at the end of
each trial, respectively. Where published reports did not
indicate timing of withdrawals, upper and lower limits
yielded high and low estimates of cost to establish treat-
ment. Average (US) wholesale prices were used for drug
costs. Statistical significance was assessed with a chi-
square test.
RESULTS: Fewer amlodipine (45%) than felodipine
(55%) patients were titrated to greater than 5 mg or dual
therapy (p  0.013). Average drug costs/patient-day
across the four studies ranged: 
Varying assumptions about timing of withdrawals
changed results by 3-percent or less. Higher costs with
felodipine were found in the study that allowed titration to
felodipine 20 mg.
CONCLUSION: The higher price of amlodipine may be
offset by higher dosages or greater need for dual therapy
with felodipine. Actual drug costs depend on dosages and
combinations used in practice.
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MANAGEMENT OF PERIPHERAL ARTERIAL 
DISEASE (PAD) PATIENTS: MODELLING THE 
RISK OF ISCHEMIC EVENTS AND THEIR 
ECONOMIC CONSEQUENCES
Levy E1, Gabriel S2, Dinet J2, Carita P2
1Université Paris IX Dauphine, Paris, France; 2Health Economics 
& Outcome Research Department, Sanofi-Synthelabo, Gentilly, 
France
OBJECTIVES: The prevalence of PAD is known to be
underestimated as a large percentage of patients are not
diagnosed. As PAD is a risk marker of atherothrombotic
disease, potential ischemic events (ischemic stroke, myo-
cardial infarction) have to be taken into account while
studying the economic burden of PAD.
METHODS: A hypothetical cohort of 1000 patients with
established PAD was used for studying, on a 2-year fol-
low-up period basis, the average management of PAD pa-
tients with and without complications (amputations, is-
chemic stroke, myocardial infarction). Probabilities of
occurrence of ischemic events came from previous large
clinical trials and were used in a Markov model. The
costing was performed using French data costs.
RESULTS: The average cost of management of a PAD
patient over a two-year period was assessed taking into
account the probability of occurrence of complications
(amputation, ischemic stroke, myocardial infarction)
without any preventive treatment. This cost is almost 3
times higher than the average cost of management of a
PAD patient over a two-year period without any compli-
cations (4501 Euros compared to 1707 Euros).
CONCLUSION: The evaluation of the economic burden
of PAD has to take into account the risk of occurrence of
ischemic events. In these patients, a preventive treatment
with antiplatelet agents can significantly reduce the cost
Amlodipine Felodipine
Establish treatment $1.49–$1.59 $1.17–$1.71
Maintain treatment $1.63–$1.74 $1.28–$1.98
